Instructions on How to Receive Credit
- Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
- Complete the 3 rounds of questions, post-test, and evaluation.
- After passing the post-test, print out your electronic CME certificate.
- In order to successfully complete this activity learners must achieve a minimum of 70% on the post-test.
The primary target audience for these activities is comprised of retinal specialists, although the education is appropriate for comprehensive ophthalmologists who manage and treat patients with DME and AMD.
This activity is supported by an educational grant from Genentech.
This activity is sponsored by the Institute for Continuing Healthcare Education.
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
It is the policy of the Institute to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All persons in control of content must disclose any significant financial interest or other relationships that may affect the content of this activity.
Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.
David S. Boyer, MD, (Chair) has disclosed the following relevant financial relationships that have occurred within the past 12 months: Alcon, Allergan, Genentech, Neurotech/A; Alcon, Aerpio, Allegro, Allergan, Bausch & Lomb, Bayer, Genentech, KalVista, Neurotech, Novartis, Regeneron, Roche, ThromboGenics/C; Allergan, Genentech/SB; and Allegro/S.
Jeffrey S. Heier, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Acucela, Aerpio, Allergan, Bausch & Lomb, Bayer, Dutch Ophthalmic, Endo Optiks, Forsight, Genzyme. Heidelberg Engineering, Kanghong, Notal Vision, Ohr Pharmaceutical, Ophthotech, QLT, Regeneron, Roche, Sequenom, Thrombogenics, Vertex, Xcovery/C; and Aerpio, Alcon, Alimera, Allergan, Fovea, Genentech, Genzyme, GlaxoSmithKiline, Neovista, Notal Vision, Novartis, Ophthotech, Paloma, Regeneron/G.
Michael S. Ip, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Eye Technology, Ltd., Genentech, Neuronetics, Valeant/C; and Allergan/G.
Christina Ohnsman, MD, has disclosed the following relevant financial relationships that have occured within the past 12 months: Alcon/A,SB.
Tim Donald as disclosed that he has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
Activity Development & Management Team
Cathy Pagano, CCMEP; Allison Muller, Pharm.D, D.ABAT; Scott Kober, MBA, CCMEP; April Reynolds MS, ELS; Sandra Davidson; and Megan Small; are employees of the Institute and are collectively responsible for the planning, development, and management of this CME activity. These individuals have disclosed that they have had no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.Con